title: Intravitreal ranibizumab for type 3 choroidal neovascularization complicating adult onset foveomacular vitelliform dystrophy.
abstract: OBJECTIVE
  To describe the results obtained with intravitreal ranibizumab injections in a patient with adult onset foveomacular vitelliform dystrophy (AOFVD) complicated by Type 3 choroidal neovascularization (CNV).
  
  
  METHODS
  A 78-year old man diagnosed with AOFVD presented at our department for decreased vision in his left eye (LE) (20/80). Upon a complete ophthalmologic examination, including fluorescein angiography, indocyanine green angiography, and spectral-domain optical coherence tomography, the patient was diagnosed with Type 3 CNV. Three monthly injections of ranibizumab 0.05 ml/0.5mg were administered intravitreally without complications.
  
  
  RESULTS
  After the first injection, visual acuity of the LE improved (20/64) and regression of the Type 3 CNV was observed by fluorescein angiography, indocyanine green angiography and OCT. Six months after the final ranibizumab injection, a more-or-less complete resolution of the exudative retinal changes was observed.
  
  
  CONCLUSIONS
  Type 3 CNV may be associated with AOFVD. Intravitreal ranibizumab may represent a possible therapeutic option in this unusual context.
authors.affiliation: Department of Ophthalmology, University Paris XII, Centre Hospitalier Intercommunal de Créteil, 40 Avenue de Verdun, 94000 Créteil, France. giuseppe.querques@hotmail.it
authors.forename: G
authors.initials: G
authors.lastname: Querques
authors.forename: L
authors.initials: L
authors.lastname: Querques
authors.forename: N
authors.initials: N
authors.lastname: Leveziel
authors.forename: F
authors.initials: F
authors.lastname: Bandello
authors.forename: E H
authors.initials: EH
authors.lastname: Souied
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D020256:Choroidal Neovascularization / Q000145:classification / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D000069579:Ranibizumab; D057826:Vitelliform Macular Dystrophy / Q000150:complications / Q000188:drug therapy*
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000069579:Ranibizumab